Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) shares rose 1% on Monday . The company traded as high as $1.06 and last traded at $1.06. 1,535 shares were traded during mid-day trading, a decline of 52% from the average session volume of 3,211 shares. The stock had previously closed at $1.05.
Vaccinex Stock Performance
The firm has a market cap of $2.60 million, a P/E ratio of -0.02 and a beta of 1.10. The company’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.01.
Vaccinex Company Profile
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Featured Articles
- Five stocks we like better than Vaccinex
- The Ultimate Cyber Shield: CrowdStrike Rises Past $235
- Palantir Just Told Wall Street Where AI Infrastructure Is Headed
- Homebuilders Are Down for the Year, Is Wall Street in Denial?
- Turning Trash to Cash: A $129M Bet on Waste
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
